Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on March 6, 2007, to disclose receipt of a request for information from Representative Henry A. Waxman, Chairman of the U.S. House of Representatives Committee on Oversight and Government Reform. The inquiry, dated February 28, 2007, specifically concerns the company's TAXUS® paclitaxel-eluting coronary stents. This filing is primarily for disclosure purposes under Regulation FD and does not constitute a formal admission or contain detailed financial statements. Investors should note that the company is cooperating with the request and has provided related press releases and the form of the inquiry letter as exhibits. The nature and potential impact of this congressional inquiry on the company's operations or product sales remain to be seen, and further updates will be crucial for assessing any material developments.
Key Highlights
- 1Boston Scientific received a request for information from a U.S. House of Representatives Committee on February 28, 2007.
- 2The inquiry specifically pertains to the company's TAXUS® paclitaxel-eluting coronary stents.
- 3The company issued a press release on March 5, 2007, to announce and disclose this information.
- 4This 8-K filing is made under Regulation FD to ensure public disclosure of material information.
- 5Exhibits include the March 5, 2007 press release and the form of the inquiry letter.
- 6The filing is for informational purposes and does not contain new financial statements or detailed operational updates beyond the disclosure of the inquiry.